ACC: Niacin/Laropiprant no benefit in vascular disease

March 12, 2013
ACC: niacin/Laropiprant no benefit in vascular disease
For patients with preexisting occlusive vascular disease, the combination of niacin and the anti-flushing agent laropiprant provides no benefit and is associated with an increase in serious side effects, according to a study presented at the annual meeting of the American College of Cardiology, held from March 9 to 11 in San Francisco.

(HealthDay)—For patients with preexisting occlusive vascular disease, the combination of niacin and the anti-flushing agent laropiprant provides no benefit and is associated with an increase in serious side effects, according to a study presented at the annual meeting of the American College of Cardiology, held from March 9 to 11 in San Francisco.

Jane M. Armitage, M.B.B.S., from the University of Oxford in the United Kingdom, and colleagues randomized 25,673 patients with preexisting occlusive vascular disease at 245 hospitals in six countries to receive daily active extended release (ER) niacin/laropiprant or placebo in addition to background low-density lipoprotein-lowering therapy.

Over four years of follow-up, the researchers found that the number of major vascular events (defined as a composite of non-fatal or coronary death, any stroke, or any arterial ) was similar for patients receiving ER niacin/laropiprant or placebo (13.2 versus 13.7 percent; P = 0.29). Patients treated with ER niacin/laropiprant had a significant excess of bleeding (2.5 versus 1.9 percent) and infections (8.0 versus 6.6 percent). Other serious side effects were significantly increased among the ER niacin/laropiprant-treated patients, including new-onset diabetes, , such as indigestion and diarrhea, and skin issues such as itching and rashes.

"We are disappointed that these results did not show benefits for our patients," Armitage said in a statement. "Still, finding out a drug is not helping people is just as important as finding that it has benefits—the net result is that people are healthier. has been used for many years in the belief that it would help patients and prevent heart attacks and stroke, but we now know that its adverse side effects outweigh the benefits when used with current treatments."

The study was funded by a grant from Merck, which provided the study drugs.

Explore further: Niacin therapy unhelpful, occasionally harmful, study says

More information: Press Release
More Information

Related Stories

Merck says cholesterol drug failed to show benefit

December 20, 2012

Drugmaker Merck & Co. said it will not seek U.S. approval for its cholesterol drug Tredaptive and is recommending doctors abroad stop prescribing it to new patients, based on failed study results.

Extended-Release niacin raises fasting glucose levels

March 28, 2012

(HealthDay) -- The combination of extended-release niacin (N) with ezetimibe plus simvastatin (E/S) to treat hyperlipidemia is associated with increased fasting glucose (FG) levels compared with E/S alone, but these cases ...

Recommended for you

Optimism may reduce risk of dying prematurely among women

December 7, 2016

Having an optimistic outlook on life—a general expectation that good things will happen—may help people live longer, according to a new study from Harvard T.H. Chan School of Public Health. The study found that women ...

New discovery at heart of healthy cereals

December 6, 2016

A new discovery at the University of Queensland could help reduce heart disease and boost nutrition security – the access to balanced nourishment - globally.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.